Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-10-05
Based on 605 first isolates · SURG · Skin / wound infection · 2024-10-06 → 2025-10-05
Surgery
Per-organism detail: SURG wound resistance view →
No single agent reaches 80 % coverage for this profile. Highest coverage without active warning:
vancomycin 56 % (52 %–60 %)
Best two-drug combination: vancomycin + meropenem covers 99 % (98 %–100 %)
Take cultures before treatment; consider a combination and discuss with infectious diseases if the patient is severely ill.
Not covered: Pseudomonas aeruginosa (13 %), Escherichia coli (12 %), Proteus mirabilis (8 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
vancomycin VAN
trend · Staphylococcus aureus Gram-positive only
56 %
58 %
n = 43
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
44 %
44 %
n = 43
meropenem MEM
trend · Pseudomonas aeruginosa reserve
43 %
42 %
n = 43
piperacillin-tazobactam TZP
trend · Pseudomonas aeruginosa broad spectrum
41 %
37 %
n = 43
40 %
37 %
n = 43
ceftriaxone CRO
trend · Escherichia coli
27 %
23 %
n = 43
25 %
26 %
n = 43
21 %
21 %
n = 43
11 %
12 %
n = 43
mecillinam MEC
not for this site
0 %
0 %
n = 43
trimethoprim TMP
not for this site
0 %
0 %
n = 43
nitrofurantoin NIT
not for this site
0 %
0 %
n = 43

Most likely organisms for this profile

Staphylococcus aureus
46 %
Pseudomonas aeruginosa
13 %
Escherichia coli
12 %
Enterococcus faecalis
10 %
Proteus mirabilis
8 %
Citrobacter freundii
6 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.